Abera Mahlet, Suresh Suchith B, Malireddi Aparna, Boddeti Sruthi, Noor Khutaija, Ansar Mehwish, Malasevskaia Iana
Medicine, Saint Paul's Millennium Medical College, Addis Ababa, ETH.
Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2024 Oct 29;16(10):e72596. doi: 10.7759/cureus.72596. eCollection 2024 Oct.
Nonalcoholic fatty liver disease (NAFLD), now recognized as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common chronic liver condition characterized by hepatic steatosis and inflammation, with an increased risk of developing fibrosis and cirrhosis. This systematic review aims to evaluate the effects of vitamin E supplementation on liver enzymes and histological features in patients with NAFLD/MASLD. We conducted a comprehensive literature search from July 14, 2024, to July 30, 2024, across multiple databases, including PubMed, MEDLINE, ScienceDirect, Europe PMC, the Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and Embase. The included studies consisted of randomized controlled trials (RCTs), clinical trials, and observational studies that evaluated the effects of vitamin E on liver enzymes (ALT and AST) and histological outcomes (steatosis, inflammation, and fibrosis) in adults diagnosed with NAFLD or NASH. A total of 11 studies were analyzed in the final review. Our results indicate that vitamin E supplementation significantly reduces serum aminotransferases and improves histological parameters such as steatosis and inflammation. However, the evidence regarding its efficacy in enhancing fibrosis remains inconclusive, highlighting a significant gap in the current literature. Vitamin E substantially improves liver function and reduces inflammation in patients with NAFLD/MASLD. However, its role in resolving fibrosis remains uncertain, indicating the need for more rigorous, long-term studies to understand its potential to reverse or halt fibrosis progression fully. Further research is required to determine its long-term effects and therapeutic potential, particularly in advanced stages of liver disease.
非酒精性脂肪性肝病（NAFLD），现被认定为代谢功能障碍相关脂肪性肝病（MASLD），是一种常见的慢性肝脏疾病，其特征为肝脂肪变性和炎症，发生纤维化和肝硬化的风险增加。本系统评价旨在评估补充维生素E对NAFLD/MASLD患者肝酶和组织学特征的影响。我们于2024年7月14日至2024年7月30日在多个数据库进行了全面的文献检索，包括PubMed、MEDLINE、ScienceDirect、欧洲生物医学与健康科学电子图书馆（Europe PMC）、Cochrane对照试验中心注册库（CENTRAL）、ClinicalTrials.gov和Embase。纳入的研究包括随机对照试验（RCT）、临床试验和观察性研究，这些研究评估了维生素E对诊断为NAFLD或NASH的成年人肝酶（ALT和AST）和组织学结果（脂肪变性、炎症和纤维化）的影响。最终评价共分析了11项研究。我们的结果表明，补充维生素E可显著降低血清转氨酶，并改善诸如脂肪变性和炎症等组织学参数。然而，关于其在改善纤维化方面疗效的证据仍不明确，凸显了当前文献中的一个重大空白。维生素E可显著改善NAFLD/MASLD患者的肝功能并减轻炎症。然而，其在解决纤维化方面的作用仍不确定，这表明需要更严格的长期研究来充分了解其逆转或阻止纤维化进展的潜力。需要进一步研究以确定其长期影响和治疗潜力，特别是在肝病晚期。
